On the individual surrogate paradox

Author:

Ma Linquan1,Yin Yunjian2,Liu Lan3,Geng Zhi2

Affiliation:

1. University of Wisconsin-Madison, 1300 University Ave., Madison, WI, USA and School of Statistics, University of Minnesota at Twin Cities, 224 Church St., Minneapolis, MN, USA

2. School of Mathematical Sciences, Peking University, Beijing, China

3. School of Statistics, University of Minnesota at Twin Cities, Minneapolis, 224 Church St., MN, USA

Abstract

SUMMARY When the primary outcome is difficult to collect, a surrogate endpoint is typically used as a substitute. It is possible that for every individual, the treatment has a positive effect on the surrogate, and the surrogate has a positive effect on the primary outcome, but for some individuals, the treatment has a negative effect on the primary outcome. For example, a treatment may be substantially effective in preventing the stroke for everyone, and lowering the risk of stroke is universally beneficial for life expectancy; however, the treatment may still cause death for some individuals. We define such paradoxical phenomenon as the individual surrogate paradox. The individual surrogate paradox is proposed to capture the treatment effect heterogeneity, which is unable to be described by either the surrogate paradox based on average causal effect or that based on distributional causal effect. We investigate the existing surrogate criteria in terms of whether the individual surrogate paradox could manifest. We find that only the strong binary surrogate can avoid such paradox without additional assumptions. Utilizing the sharp bounds, we propose novel criteria to exclude the individual surrogate paradox. Our methods are illustrated in an application to determine the effect of the intensive glycemia on the risk of development or progression of diabetic retinopathy.

Publisher

Oxford University Press (OUP)

Subject

Statistics, Probability and Uncertainty,General Medicine,Statistics and Probability

Reference31 articles.

1. Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes;Albert,;Biometrical Journal: Journal of Mathematical Methods in Biosciences,2005

2. Warfarin: balancing the benefits and harms;Borosak,;Australian Prescriber,2004

3. Criteria for the validation of surrogate endpoints in randomized experiments;Buyse,;Biometrics,1998

4. The validation of surrogate endpoints in meta-analyses of randomized experiments;Buyse,;Biostatistics,2000

5. Criteria for surrogate end points;Chen,;Journal of the Royal Statistical Society: Series B (Statistical Methodology),2007

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3